From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Sunitinib is a standard first-line therapy for metastatic renal cell carcinoma (mRCC), pancreatic neuroendocrine tumors, and imatinib-resistant gastrointestinal stromal tumors (GIST).
• Most patients develop intrinsic or acquired resistance to sunitinib, limiting its long-term efficacy.
• The role of autophagy in sunitinib sensitivity and resistance is complex and debated.

Purpose of the Study:

• To review the role of prosurvival signaling pathways and autophagy in mediating sunitinib resistance.
• To identify potential prognostic biomarkers for sunitinib responsiveness.
• To discuss innovative therapeutic strategies to overcome sunitinib resistance.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of signaling pathways involved in drug resistance.
• Exploration of the interplay between autophagy and sunitinib treatment.

Main Results:

• A network of prosurvival signaling pathways has been identified as key mediators of sunitinib resistance.
• These pathways have established and emerging functions as autophagy regulators.
• Potential prognostic biomarkers for sunitinib responsiveness have been underscored.

Conclusions:

• Understanding the molecular mechanisms of sunitinib resistance is crucial for optimizing therapeutic responses.
• Identifying biomarkers can aid in patient stratification and personalized therapy.
• Innovative strategies targeting signaling pathways and autophagy hold promise for overcoming sunitinib resistance and improving clinical outcomes.